Published in Br J Pharmacol on January 28, 2008
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol (2010) 1.08
Cardioprotection during cardiac surgery. Cardiovasc Res (2012) 1.03
Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol (2012) 1.02
The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol (2010) 1.01
Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res (2009) 0.97
Endothelium-derived endothelin-1. Pflugers Arch (2009) 0.97
Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? Br J Pharmacol (2014) 0.93
Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts. Am J Physiol Heart Circ Physiol (2011) 0.92
Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol (2012) 0.92
Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations. J Mol Cell Cardiol (2013) 0.92
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol (2008) 0.91
Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol (2010) 0.88
Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PLoS One (2012) 0.86
Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens (2012) 0.85
Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia. Mol Med (2012) 0.84
Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol (2015) 0.84
Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf (2014) 0.82
Added prognostic value of ischaemic threshold in radionuclide myocardial perfusion imaging: a common-sense integration of exercise tolerance and ischaemia severity. Eur J Nucl Med Mol Imaging (2014) 0.82
Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol (2016) 0.81
Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther (2014) 0.81
Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry. Clin Res Cardiol (2014) 0.81
Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation. Front Physiol (2012) 0.79
Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J (2009) 0.79
Prognostic value of resting heart rate on cardiovascular and renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohort. Diabetes Care (2012) 0.78
Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol (2013) 0.78
Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action? Cardiovasc Drugs Ther (2011) 0.78
Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clin Res Cardiol (2014) 0.78
Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice. Adv Ther (2016) 0.77
Effect of adrenergic agonists on coronary blood flow: a laboratory study in healthy volunteers. Physiol Rep (2016) 0.76
In silico coronary wave intensity analysis: application of an integrated one-dimensional and poromechanical model of cardiac perfusion. Biomech Model Mechanobiol (2016) 0.76
Orientation dependence of microcirculation-induced diffusion signal in anisotropic tissues. Magn Reson Med (2015) 0.76
Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag (2016) 0.75
The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy. Front Pharmacol (2016) 0.75
Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade. J Cardiovasc Pharmacol (2017) 0.75
Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther (2015) 0.75
Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. J Am Heart Assoc (2017) 0.75
Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice. Cardiol Ther (2017) 0.75
Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature (2003) 4.80
Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am J Physiol (1963) 4.04
Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res (1972) 3.53
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation (2003) 1.86
Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs (2004) 1.85
Understanding the coronary circulation through studies at the microvascular level. Circulation (1990) 1.76
Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension (1999) 1.71
Alpha-adrenergic mechanisms in myocardial ischemia. Circulation (1990) 1.68
Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol (1994) 1.57
CONTROL OF CORONARY BLOOD FLOW BY AN AUTOREGULATORY MECHANISM. Circ Res (1964) 1.57
Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation (2004) 1.55
Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation (1991) 1.54
alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation (2000) 1.44
An analysis of the mechanical disadvantage of myocardial infarction in the canine left ventricle. Circ Res (1980) 1.44
Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation (2001) 1.37
Retarding effect of lowered heart rate on coronary atherosclerosis. Science (1984) 1.35
Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J (2004) 1.26
Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol (1990) 1.25
Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther (1995) 1.15
Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation (1999) 1.14
Effect of exercise on the relationship between myocardial blood flow and systolic wall thickening in dogs with acute coronary stenosis. Circ Res (1983) 1.14
Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol (2002) 1.06
Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther (2003) 1.05
Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res (1987) 1.04
Phasic coronary blood flow velocity in intramural and epicardial coronary arteries. Circ Res (1982) 1.03
Regional myocardial perfusion and wall thickening during ischemia in conscious dogs. Am J Physiol (1984) 1.02
The distribution of functional impairment across the lateral border of acutely ischemic myocardium. Circ Res (1986) 1.01
Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol (1990) 1.00
Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation (1997) 1.00
Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol (2002) 0.99
Dynamics of flow velocities in endocardial and epicardial coronary arterioles. Am J Physiol Heart Circ Physiol (2004) 0.98
Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol (2003) 0.95
Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation (1989) 0.94
Effects of a calcium-entry blocker (diltiazem) on regional myocardial flow and function during exercise in conscious dogs. Circulation (1984) 0.94
Mechanisms of augmented segment shortening in nonischemic areas during acute ischemia of the canine left ventricle. Circ Res (1985) 0.93
Feedforward control of coronary blood flow via coronary beta-receptor stimulation. Circ Res (1993) 0.91
Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther (2001) 0.91
Effects of beta-blockade on regional myocardial flow and function during exercise. Am J Physiol (1984) 0.90
Left ventricular asynchrony: an indicator of regional myocardial dysfunction. Am Heart J (1990) 0.89
I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol (2004) 0.88
Ischemic myocardial dysfunction assessed by temporal Fourier transform of regional myocardial wall thickening. Am Heart J (1987) 0.87
Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res (1988) 0.86
Post-ejection wall thickening as a marker of successful short term hibernation. Cardiovasc Res (1993) 0.86
Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol. J Cardiovasc Pharmacol (1995) 0.84
Coronary microcirculation: autoregulation and metabolic control. Basic Res Cardiol (1995) 0.84
Decreased systolic wall thickening in myocardium adjacent to ischemic zones in conscious swine during brief coronary artery occlusion. Am Heart J (1984) 0.83
Contribution of KATP+ channels to coronary vasomotor tone regulation is enhanced in exercising swine with a recent myocardial infarction. Am J Physiol Heart Circ Physiol (2004) 0.83
Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning. Eur Heart J (2007) 0.83
Mechanism of coronary microvascular responses to metabolic stimulation. Cardiovasc Res (1997) 0.82
Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia. Eur Heart J (1987) 0.82
Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart. Circulation (1981) 0.81
The role of heart rate in myocardial ischemia and infarction: implications of myocardial perfusion-contraction matching. Prog Cardiovasc Dis (1993) 0.81
Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol (1990) 0.80
A proischaemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole. Cardiovasc Res (1993) 0.80
Effect of the combination of diltiazem and atenolol on exercise-induced regional myocardial ischemia in conscious dogs. Circulation (1985) 0.80
Experimental exercise-induced ischemia: drug therapy can eliminate regional dysfunction and oxygen supply-demand imbalance. J Am Coll Cardiol (1986) 0.80
Effects of heart rate on hemodynamic severity of coronary artery stenosis in the dog. Basic Res Cardiol (1983) 0.79
Neuronal control of coronary blood flow. Basic Res Cardiol (1995) 0.79
Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflugers Arch (1983) 0.79
Metoprolol reduces 'compensatory' coronary blood flow following occlusion of an adjacent branch without altering post-occlusion hyperaemia. Life Sci (2005) 0.79
Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening. Br J Pharmacol (2006) 0.79
Augmentation of regional function in nonischemic myocardium during coronary occlusion measured with two-dimensional echocardiography. J Am Coll Cardiol (1990) 0.78
The functional border zone in conscious dogs. Circulation (1987) 0.78
Beta-receptor subtypes in the canine coronary circulation. Am J Physiol (1990) 0.77
Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg (Torino) (2006) 0.76
Adverse effects of circumflex coronary artery occlusion on blood flow to remote myocardium supplied by a stenosed left anterior descending coronary artery in anesthetized open-chest dogs. Am Heart J (1987) 0.76